A message from Stocks.News 
Why Shuttle Pharmaceuticals (NASDAQ: SHPH) Is Emerging as a High-Impact Oncology Stock to Watch for 2026. The global push for more effective cancer treatments is accelerating, and Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) is positioning itself at the center of this shift. As demand rises across oncology, radiation therapy, and diagnostics, the need for therapies that enhance treatment outcomes and improve quality of life has never been greater. Shuttle Pharmaceuticals is addressing this demand through a focused strategy centered on precision medicine, radiation sensitizers, and targeted cancer solutions. At the core of its pipeline is Ropidoxuridine (IPdR) a radiation sensitizer being developed to improve the effectiveness of radiation therapy for glioblastoma—one of the most aggressive and difficult-to-treat brain cancers. Importantly, IPdR has received Orphan Drug Designation from the U.S. Food and Drug Administration, which may provide marketing exclusivity upon first FDA approval for the treatment of glioblastoma. This designation highlights both the seriousness of the disease and the potential clinical importance of SHPH’s approach. Beyond its lead program, the company is advancing novel HDAC inhibitors, PSMA-B ligand therapeutics for prostate cancer, and the PC-Rad Test, a predictive diagnostic designed to guide radiation therapy decisions. Supported by strategic collaborations, innovative research, and a strong intellectual property foundation, SHPH is building a diversified platform aimed at advancing the future of cancer care. Discover how SHPH could shape the future of radiation-based cancer treatment while building shareholder value. | 
